Aiming at the Future of Precision Medicine Market Primo Biotechnology recently completed its seed round of funding, led by AVA Angels. The seed round successfully raised 4 million, combined with 2.5 million from the angel round, resulting in a total capital increase of 6.5 million for Primo Biotechnology within just two years of its establishment….

Dr. Chi-Wei Chang, a highly-experienced radiochemist in the field of radiopharmaceuticals in Taiwan, has been dedicated in the field of positron radiopharmaceutical synthesis for more than 30 years and had received a Ph. D of the department of Biomedical Imaging and Radiological Sciences in National Yang-Ming University (it’s now renamed as National Yang-Ming Chiao-Tung University)…

Primo Biotechnology aims to provide precision medicine and benefit the cancer patient. We decided to launch the Tackle Cancer Challenge – Radiotheranostics on the move with the Oncidium foundation : a campaign encouraging everyone to exercise together to reach the goal of 5000 kilometers and to help to increase awareness about radiotheranostics in cancer care….

In order to speed the development of precision medicine and benefit the cancer patient, the Belgium based nonprofit organization Oncidium is established since 2011. Oncidium takes the mission to support and accelerate the growth and the use of novel radiopharmaceuticals for cancer treatment, without the concern of source, skills and finance status. Oncidium is dedicated…